Statin treatment: myths and reality
Abstract
Aim. To assess effectiveness and tolerability of rosuvastatin treatment, as a part of primary and secondary cardiovascular prevention, in patients with high and very high cardiovascular risk and dyslipidemia.
Material and methods. Forty patients received rosuvastatin (starting dose 10 mg/d) for 12 weeks. At baseline, medical history collection, physical and instrumental examination, blood biochemical assay (creatinine, glucose, lipids, aminotransferase, bilirubin, urea levels) and general urine assay were performed. Four and 12 weeks later, complex assessment of rosuvastatin effectiveness and safety took place. If target levels of low- or high-density lipoprotein cholesterol (FDF-CH, <2,6 mmol/1; HDF-CH, >1,2 mmol/1) were not achieved, rosuvastatin dose increased up to 20 mg/d. After 4 and 12 weeks, all parameters measured previously were re-assessed, including patients' complaints, therapy compliance, and adverse effects, if any.
Results. After 4 and 12 weeks of rosuvastatin treatment, lipid profile normalized in most patients, target FDF-CH, HDF-CH, and triglyceride levels were achieved in 63 %, 65 %, and 68 %, respectively. Mean rosuvastatin dose was 10,6 mg/d. Fhe medication was well tolerated.
Conclusion. Rosuvastatin demonstrated not only high lipid-lowering effectiveness, but also good tolerability.
About the Authors
L. A. Malay
Medical Center, Khabarovsk Region Federal Security Service. Khabarovsk
Russian Federation
Russian Federation
B. V. Sharykin
Medical Center, Khabarovsk Region Federal Security Service. Khabarovsk
Russian Federation
Russian Federation
A. N. Miroshnichenko
Medical Center, Khabarovsk Region Federal Security Service. Khabarovsk
Russian Federation
Russian Federation
V. V. Konurovsky
Medical Center, Khabarovsk Region Federal Security Service. Khabarovsk
Russian Federation
Russian Federation
E. E. Kusnetsova
Medical Center, Khabarovsk Region Federal Security Service. Khabarovsk
Russian Federation
Russian Federation
O. I. Vasina
Medical Center, Khabarovsk Region Federal Security Service. Khabarovsk
Russian Federation
Russian Federation
References
1. Staffa J.A., Chang J., Green L. Cerifastatin and repots of fatal rhabdomyolis [letter]. N Engl J Med 2002; 346: 539-40.
2. Gotto A.M.G.Jr. Statins, cardiovascular disease, and safety. Am J Cardiol 2006; 97(Suppl): 3C-5.
3. Cohen D.E., Anania F.A., Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97(Suppl): 77C-81.
4. Law M., Rudniska A.R. Statin safety: a systematic review. Am J Cardiol 2006; 97(Suppl): 6C-26.
5. Fried L.F., Orchard T.J., Kasiske B.L., for the Lipids and Renal Disease Progression Meta-analysis Study Group. Effect of lipid reduction on the progression of renal disease: A metaanalysis. Kidney Int 2001; 59: 260-9.
6. Sparks D.L., Sabbagh M.N., Connor D.J. et al. Atorvastatin for the treatment of mild to moderate Alzheimer diasease. Arch Neurol 2005; 62: 753-7.
7. Zamrini E., McGwin G., Roseman L.M. Association between statin use and Alzheimer diasease. Neuroepidemiology 2004; 23: 94-8.
8. Jick H., Zoenberg G.L., Jick S. et al. Statins and risk of dementia. Lancet 2000; 356: 1627-31.
9. Jacobson Т.А. Statin safety: lessons from New Drug Applications for marketed statins. Am J Cardiol 2006; 97(Suppl): 44C-51.
10. US Food and Drug Administration. Center for Drug Evaluation and Reserch. Approval Package for Application Number 21-366.
11. Yamamoto A., Sudo H., and Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis 1980; 35: 259-66.
12. Scandinavian Simvistatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 pations with coronary heart disease: the Scandinavian Simvistatin Survival Study (4S). Lancet 1994; 344: 1383-9.
13. Baigent C., Keech A., Kearney P.M. et al. Efficacy and safety of cholesterol lowering treatment: prospective meta-anaysis of data from 90,056 participans in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
14. Brown M.S. and Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
15. MRS/BHF Heart Protection Study of cholesterol lowering with simvistatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
16. Shepherd J., Cobbe S.M., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J med 1995; 333: 1301-7.
17. Downs J.R., Clearfield M., Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
18. Джаиани Н.А., Ильина Е.В., Терещенко С.Н. Современные аспекты применения статинов при остром инфаркте миокарда. Сердце 2007; 6(2): 85-8.
19. Затейщиков Д.А. Розувастатин: новые возможности борьбы с атеросклерозом. Фарматека 2004; 14: 12-8.
20. Рекомендации рабочей группы по безопасности статинов национальной ассоциации липидологов США. Доказат кардиол 2007; 1: 40-7.
21. Nissen S. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA 2006; 295(13): 1556-1565.
22. И.Е. Чазова, В.В. Кухарчук, Л.Е. Ратова и др. Возможности гиполипидемической терапии больных артериальной гипертонией (по результатам программы "РОЗА" -РОЗувастатин у пациентов с Артериальной гипертонией. Системные гипертензии 2007; 2:3-6.
23. Мареев В.Ю., Даниелян М.О. Крестор: Эффективность и Безопасность у больных ишемической болезнью сердца (дизайн и основные результаты исследования КЭБ). Сердце 2008; 7(1): 65-70.
Review
For citations:
Malay L.A., Sharykin B.V., Miroshnichenko A.N., Konurovsky V.V., Kusnetsova E.E., Vasina O.I. Statin treatment: myths and reality. Cardiovascular Therapy and Prevention. 2008;7(3):95-100. (In Russ.)
Views:
559
Email this article 
